Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis

OBJECTIVES: The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF).; BACKGROUND: CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has...

Descripción completa

Detalles Bibliográficos
Autores: Nunez, Julio, Bayes-Genis, Antoni, Revuelta-Lopez, Elena, Ter Maaten, Jozine M, Minana, Gema, Barallat, Jaume, Cserkoova, Adriana, Bodi, Vicent, Fernandez-Cisnal, Agustin, Nunez, Eduardo, Sanchis, Juan, Lang, Chim, Ng, Leong L, Metra, Marco, Voors, Adriaan A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p4287
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/4287
Access Level:acceso abierto
Palabra clave:CA125
carbohydrate antigen 125
congestion
outcome
worsening heart failure
id ES_55bed9ab7dd7d466fc6afba80eea8a6d
oai_identifier_str oai:incliva.fundanetsuite.com:p4287
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study SubanalysisNunez, JulioBayes-Genis, AntoniRevuelta-Lopez, ElenaTer Maaten, Jozine MMinana, GemaBarallat, JaumeCserkoova, AdrianaBodi, VicentFernandez-Cisnal, AgustinNunez, EduardoSanchis, JuanLang, ChimNg, Leong LMetra, MarcoVoors, Adriaan ACA125carbohydrate antigen 125congestionoutcomeworsening heart failureOBJECTIVES: The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF).; BACKGROUND: CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification.; METHODS: In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by using the Royston-Parmar method (N=2,356). In a sensitivity analysis, the prognostic implications of CA125 were also adjusted for a composite congestion score (CCS). Data were validated in the BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic HeartFailure validation) cohort (N=1,630).; RESULTS: Surrogates of congestion, such as N-terminal pro-B-type natriuretic peptide and CCS, emerged as independent predictors of CA125. In multivariable survival analyses, higher CA125 was associated with an increased risk of mortality and the composite of death/HF readmission (p<0.001 for both comparisons), even after adjustment for the CCS (p<0.010 for both comparisons). The addition of CA125 to the BIOSTAT score led to a significant risk reclassification for both outcomes (category-free net reclassification improvement=0.137 [p<0.001] and 0.104 [p=0.003] respectively). All outcomes were confirmed in an independent validation cohort.; CONCLUSIONS: In patients with worsening HF, higher levels of CA125 were positively associated with parameters of congestion. Furthermore, CA125 remained independently associated with a higher risk of clinical outcomes, evenbeyonda predefined risk model and clinical surrogates of congestion. Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.ELSEVIER SCI LTD2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/4287JACC-Heart FailureISSN: 22131779ISSNe: 22131787reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p42872026-06-07T16:35:31Z
dc.title.none.fl_str_mv Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
title Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
spellingShingle Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
Nunez, Julio
CA125
carbohydrate antigen 125
congestion
outcome
worsening heart failure
title_short Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
title_full Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
title_fullStr Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
title_full_unstemmed Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
title_sort Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis
dc.creator.none.fl_str_mv Nunez, Julio
Bayes-Genis, Antoni
Revuelta-Lopez, Elena
Ter Maaten, Jozine M
Minana, Gema
Barallat, Jaume
Cserkoova, Adriana
Bodi, Vicent
Fernandez-Cisnal, Agustin
Nunez, Eduardo
Sanchis, Juan
Lang, Chim
Ng, Leong L
Metra, Marco
Voors, Adriaan A
author Nunez, Julio
author_facet Nunez, Julio
Bayes-Genis, Antoni
Revuelta-Lopez, Elena
Ter Maaten, Jozine M
Minana, Gema
Barallat, Jaume
Cserkoova, Adriana
Bodi, Vicent
Fernandez-Cisnal, Agustin
Nunez, Eduardo
Sanchis, Juan
Lang, Chim
Ng, Leong L
Metra, Marco
Voors, Adriaan A
author_role author
author2 Bayes-Genis, Antoni
Revuelta-Lopez, Elena
Ter Maaten, Jozine M
Minana, Gema
Barallat, Jaume
Cserkoova, Adriana
Bodi, Vicent
Fernandez-Cisnal, Agustin
Nunez, Eduardo
Sanchis, Juan
Lang, Chim
Ng, Leong L
Metra, Marco
Voors, Adriaan A
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CA125
carbohydrate antigen 125
congestion
outcome
worsening heart failure
topic CA125
carbohydrate antigen 125
congestion
outcome
worsening heart failure
description OBJECTIVES: The aim of this study was to evaluate the association between antigen carbohydrate 125 (CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure (HF).; BACKGROUND: CA125 is a widely available biomarker that is up-regulated in patients with acute HF and has been postulated as a useful marker of congestion and risk stratification.; METHODS: In a large multicenter cohort of patients with worsening HF, either in-hospital or in the outpatient setting, the independent associations between CA125 and 1-year death and the composite of death/HF readmission (adjusted for outcome-specific prognostic risk score [BIOSTAT risk score]) were determined by using the Royston-Parmar method (N=2,356). In a sensitivity analysis, the prognostic implications of CA125 were also adjusted for a composite congestion score (CCS). Data were validated in the BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic HeartFailure validation) cohort (N=1,630).; RESULTS: Surrogates of congestion, such as N-terminal pro-B-type natriuretic peptide and CCS, emerged as independent predictors of CA125. In multivariable survival analyses, higher CA125 was associated with an increased risk of mortality and the composite of death/HF readmission (p<0.001 for both comparisons), even after adjustment for the CCS (p<0.010 for both comparisons). The addition of CA125 to the BIOSTAT score led to a significant risk reclassification for both outcomes (category-free net reclassification improvement=0.137 [p<0.001] and 0.104 [p=0.003] respectively). All outcomes were confirmed in an independent validation cohort.; CONCLUSIONS: In patients with worsening HF, higher levels of CA125 were positively associated with parameters of congestion. Furthermore, CA125 remained independently associated with a higher risk of clinical outcomes, evenbeyonda predefined risk model and clinical surrogates of congestion. Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/4287
url https://incliva.portalinvestigacion.com/publicaciones/4287
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCI LTD
publisher.none.fl_str_mv ELSEVIER SCI LTD
dc.source.none.fl_str_mv JACC-Heart Failure
ISSN: 22131779
ISSNe: 22131787
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408329001861120
score 15.81155

Similares en LA Referencia